The Utility of the CA 19-9 Test in Patients With Pancreatic Cancer

Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.

Clinical Pearls

Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.

  • CA 19-9 is a cancer marker that can be measured in the blood and is elevated in 60-70% of patients with pancreatic cancer
  • High levels of CA 19-9 in a patient who does not otherwise have clinical features of pancreatic cancer is not helpful in obtaining a diagnosis
  • CA 19-9 is primarily used in monitoring treatment response

VisitPancreatic Cancer ActionorRoswell Park Cancer Institute